{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:11:41Z","timestamp":1780377101059,"version":"3.54.1"},"reference-count":23,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Objective: Inadequate radiation delivery to recurrent pelvic and abdominal tumors is frequently attributable to the dose limitations of surrounding normal structures, particularly the intestines. Radiotherapy guided by magnetic resonance imaging (MRI) significantly enhances the accuracy of soft-tissue delineation. The purposes of this study were to demonstrate the feasibility and effectiveness of MR-Linac Adaptive stereotactic body radiotherapy in patients with pelvic\u2013abdominal recurrent or metastatic gynecological malignancies with or without systemic therapies. Methods: Patients with pelvic\u2013abdominal recurrent or metastatic gynecological malignancies are eligible for MR-Linac Adaptive stereotactic body radiotherapy. Systemic therapies, including chemotherapy, immunotherapy, and targeted therapy, are considered acceptable treatment options. The safety, tolerability, and efficacy of MR-Linac Adaptive stereotactic body radiotherapy were assessed. Results: Between October 2019 and May 2025, 15 patients were subjected to MR-Linac Adaptive stereotactic body radiotherapy. With a median follow-up period of 4.67 months (range, 0.73\u201320.10 months), the 6-month overall survival (OS), progression-free survival (PFS), and local control (LC) rates were 93.3%, 66.0%, and 92.3%, respectively. The 12-month OS, PFS, and LC rates were 83.8%, 37.7%, and 70.5%, respectively. The best objective response rate (ORR = CR + PR) for the irradiated lesions was 73.3% (11\/15 patients). MR-Linac Adaptive stereotactic body radiotherapy led to objective responses in 73.3% (11\/15) of the patients. As of the data cutoff (28 May 2025), one patient experienced dose-limiting toxicity (an enteric fistula). Another patient developed grade 4 thrombocytopenia during treatment; it was considered chemotherapy-induced. Conclusions: These findings suggest that MR-Linac Adaptive stereotactic body radiotherapy is relatively effective and safe and can be an important treatment option for patients with pelvic\u2013abdominal recurrent or metastatic gynecological malignancies. MR-Linac Adaptive stereotactic body radiotherapy exhibited acceptable tolerability, promising efficacy, and a favorable local control rate with regard to heavily pretreated advanced solid tumors.<\/jats:p>","DOI":"10.3390\/cancers18071112","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T12:11:59Z","timestamp":1774872719000},"page":"1112","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Preliminary Results Regarding the Feasibility and Outcomes of MR-Linac Adaptive Stereotactic Body Radiotherapy Combined with Systemic Treatment Among Patients with Pelvic\u2013Abdominal Recurrent or Metastatic Gynecological Malignancies: A Single-Institution Experience"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8812-9957","authenticated-orcid":false,"given":"Xi","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Gynecological Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5319-4363","authenticated-orcid":false,"given":"Shuang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zexuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5414-9375","authenticated-orcid":false,"given":"Shuangzheng","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jusheng","family":"An","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manni","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: Final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/JCO.23.00914","article-title":"First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826","volume":"41","author":"Monk","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_3","first-page":"475","article-title":"Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II primmo study","volume":"72","author":"Tuyaerts","year":"2022","journal-title":"Cancer Immunol. Immun."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e2553809","DOI":"10.1001\/jamanetworkopen.2025.53809","article-title":"Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy","volume":"9","author":"Looman","year":"2026","journal-title":"JAMA Netw. Open"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/ijgc-2020-002031","article-title":"Use of bevacizumab before or after radiotherapy increases the risk of fistula formation in patients with cervical cancer","volume":"31","author":"Kim","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/S1470-2045(22)00447-8","article-title":"European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: Definition, reporting, and clinical decision making","volume":"23","author":"Andratschke","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s10585-020-10047-x","article-title":"Phase II trial of high dose stereotactic body radiation therapy for lymph node oligometastases","volume":"37","author":"Franzese","year":"2020","journal-title":"Clin. Exp. Metastas."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2340\/1651-226X.2025.42898","article-title":"Quantifying the dosimetric impact of online daily adaptation for MR-guided RT in cervical cancer","volume":"64","author":"Alshamrani","year":"2025","journal-title":"Acta Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.clon.2023.11.036","article-title":"Online Adaptive Magnetic Resonance-guided Radiation Therapy for Gynaecological Cancers: Preliminary Results of Feasibility and Outcome","volume":"36","author":"Ugurluer","year":"2023","journal-title":"Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.radonc.2008.04.009","article-title":"Online MRI guidance for healthy tissue sparing in patients with cervical cancer: An IMRT planning study","volume":"88","author":"Kerkhof","year":"2008","journal-title":"Radiother. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","article-title":"Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: Systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium","volume":"24","author":"Kroeze","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41419-023-06211-2","article-title":"Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref_13","first-page":"120","article-title":"Immunological impact of cell death signaling driven by radiation on the tumor microenvironment","volume":"21","author":"Vitale","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.ijrobp.2021.12.162","article-title":"Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation","volume":"112","author":"Du","year":"2022","journal-title":"INT J. Radiat. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1158\/1078-0432.CCR-18-2581","article-title":"The Reciprocity between Radiotherapy and Cancer Immunotherapy","volume":"25","author":"Wang","year":"2019","journal-title":"Clin Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","article-title":"Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: A pooled analysis of two randomised trials","volume":"9","author":"Theelen","year":"2020","journal-title":"Lancet Resp. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.eururo.2021.12.006","article-title":"Stereotactic Radiotherapy Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial","volume":"81","author":"Siva","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/ijgc-2022-004230","article-title":"Improvement in radiation techniques for locally advanced cervical cancer during the last two decades","volume":"33","author":"Sagae","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.semradonc.2020.05.007","article-title":"Incorporating Magnetic Resonance Imaging (MRI) Based Radiation Therapy Response Prediction into Clinical Practice for Locally Advanced Cervical Cancer Patients","volume":"30","author":"Schernberg","year":"2020","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Portelance, L., Corradini, S., Erickson, B., Lalondrelle, S., Padgett, K., van der Leij, F., van Lier, A., and J\u00fcrgenliemk-Schulz, I. (2021). Online Magnetic Resonance-Guided Radiotherapy (oMRgRT) for Gynecological Cancers. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.628131"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3390\/curroncol30010066","article-title":"The New Kid on the Block: Online Adaptive Radiotherapy in the Treatment of Gynecologic Cancers","volume":"30","author":"Yen","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Sherwani, Z., Parikh, S., Yegya-Raman, N., McKenna, K., Deek, M., Jabbour, S., and Hathout, L. (2023). Stereotactic Body Radiation Therapy in Gynecologic Oligometastases: An Effective but Underutilized Approach. Cancers, 15.","DOI":"10.3390\/cancers15133526"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/7\/1112\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T04:20:32Z","timestamp":1775017232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/7\/1112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":23,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["cancers18071112"],"URL":"https:\/\/doi.org\/10.3390\/cancers18071112","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]}}}